ERBB2 and neoplasm: Overall, our results suggested that METTL3 plays a pivotal tumour-suppressor role in the progression of HR+HER2− BC, indicating that METTL3 is a promising biomarker for predicting the efficacy of chemotherapy as well as a potential therapeutic target for reversing chemotherapy resistance in HR+HER2− BC.